The imminent US Marijuana Rescheduling begs the question: Is it really different this time for ASX pot stocks? In one sense, perhaps it is, because it is undoubtedly the most significant policy signal in more than 50 years. But in the other, there’s no promise it’ll lead to anything, as recent history has shown.
What’s Happening Right Now
Reports emerged on 22 April 2026 (US time) that the White House has told federal agencies to prepare to imminently loosen restrictions on marijuana, rescheduling the drug from a Schedule I controlled substance to Schedule III. The same media sources that gave these reports cautioned, however, that the administration’s plans are in flux and could change. This is consistent with how this process has unfolded for the past 18 months.
The market’s reaction was immediate and emphatic. The AdvisorShares Pure US Cannabis ETF (NYSE Arca: MSOS), the first and only US-listed ETF with dedicated, exclusively domestic cannabis exposure, surged over 25% on the news. Broader cannabis stocks and ETFs across US and international exchanges followed. For a sector that has endured years of regulatory false starts and steadily declining share prices, the move was significant.
The context matters. Cannabis currently sits on Schedule I of the US Controlled Substances Act (CSA): the same classification as heroin and LSD, substances the government deems to have no medical use and a high potential for abuse. Moving it to Schedule III would place it alongside ketamine, anabolic steroids, and Tylenol with codeine: controlled substances that have accepted medical uses and a lower potential for abuse. The symbolic shift is as meaningful as the legal one.
US Marijuana Rescheduling: Where the Process Stands and Why It’s Complicated
The groundwork for this moment stretches back years. In August 2023, the Department of Health and Human Services recommended to the DEA that marijuana be moved from Schedule I to Schedule III, based on its scientific and medical evaluation. In May 2024, the DEA proposed a rule that, if finalised, would transfer marijuana to Schedule III — attracting over 42,000 public comments. The process then stalled in bureaucratic limbo, before Trump signed Executive Order 14370 on December 18 2025 directing the Attorney General to complete the rescheduling process in the most expeditious manner in accordance with federal law.
The EO does not pre-determine any outcome from the required administrative hearing. It merely directs the Attorney General to complete the formal rulemaking process, it is not self-executing. The legal reality is also nuanced. Moving marijuana from Schedule I to Schedule III, without other legal changes, would not bring the state-legal medical or recreational marijuana industry into compliance with federal controlled substances law. Interstate commerce would remain illegal.
Marijuana itself is still not an FDA-approved drug, and the path from rescheduling to commercially available prescription products is not a straight line.
Still, the administration’s direction of travel is now unmistakable, and the market has priced that in.
The One Immediate Commercial Lever: 280E Relief
Despite the procedural complexity, one concrete benefit would follow rescheduling relatively quickly: the removal of IRS Section 280E restrictions. Because cannabis is currently a Schedule I drug, cannabis businesses cannot claim the same tax deductions available to every other business in America — including wages and ordinary operating expenses — exposing them to significantly higher effective tax rates. The biggest thing that happens overnight is the removal of 280E, the restrictive punitive tax code that does not allow cannabis companies to deduct normal expenses that everyone else can deduct.
For some larger US multi-state operators (MSOs), analysts have estimated the 280E reversal could improve EBITDA margins by 10–20 percentage points. That is real money — and it would flow through relatively quickly once a final rule takes effect. However, two bills — S.471 and H.R.1447 — have been introduced in Congress to preserve 280E restrictions even if rescheduling proceeds, adding another layer of uncertainty. Rescheduling alone will not deliver a lasting re-rating of cannabis equities; expanded institutional access and improving financial performance across operators are also required for a sustainable uplift.
The TGA Parallel: When Regulatory Headlines Don’t Move the Revenue Needle
ASX cannabis investors have been here before. In late 2020, the TGA declassified low-dose CBD products, allowing them to be obtained in pharmacies without a prescription. Investors would have thought products would be sold en masse within months, given the hype around many cannabis stocks at the time. Obviously that ship has sailed.
The TGA decision was a genuine regulatory milestone. The practical outcome was muted. While the down-scheduling allowed low-dose CBD to be sold without a doctor’s prescription, those products still needed to be registered on the Australian Register of Therapeutic Goods (ARTG) before they could legally hit pharmacy shelves. Years later, no OTC CBD product had navigated that pathway to commercial scale. Share prices that spiked on the announcement gave back those gains over the months that followed.
The US situation is structurally analogous. If and when a scheduling change happens in the sense of being formally published in the Federal Register, it will be a meaningful signal, but not an open door. FDA approval processes, DEA registration requirements, state-versus-federal inconsistencies, and potential litigation will all constrain how quickly revenue can follow. The share price rally, however, does not require any of that to materialise. It only requires the expectation that it eventually will.
Which ASX Stocks Could Benefit? A Realistic Assessment
More importantly, the ASX cannabis cohort is dominated by Australian-focused growers and clinical-stage biotechs with limited or indirect US exposure. For investors seeking genuine leverage to US rescheduling, the universe is narrow, and quality is uneven.
Zelira Therapeutics (ASX: ZLD) is the most operationally grounded ASX name with active US exposure. The Perth-based biopharmaceutical company — formed from the 2020 merger of Zelda Therapeutics and Pennsylvania-based Ilera Healthcare — holds formulations under its HOPE brand across Washington, Pennsylvania, and Louisiana, and is developing ZENIVOL, a cannabinoid treatment for chronic insomnia.
Zelira has clinical data behind its core products, which matters: rescheduling is likely to increase FDA scrutiny of cannabis medicines, favouring companies with validated clinical profiles over commoditised cultivators. The risk is scale — with revenue of just A$656 in FY25 (yes, just A$656, there’s no typo), the company remains pre-commercial by any meaningful measure, and the path from rescheduling to US product revenue is long.
Elixinol Wellness (ASX: EXL) has the most established US commercial presence of any ASX-listed name, operating hemp-derived CBD products across the Americas under its legacy Colorado-based business. Importantly, hemp-derived products are not subject to CSA scheduling in the same manner as marijuana, meaning rescheduling itself is not a direct revenue trigger for Elixinol.
However, a more permissive federal cannabis environment could reduce the regulatory ambiguity that has suppressed CBD market growth since the FDA’s enforcement actions of 2018–2021. The stock trades near penny territory as of April 2026, reflecting how commercially difficult the US CBD market has been.
Incannex Healthcare (ASX: IHL) dual-listed on Nasdaq in early 2022 as IXHL, giving it US capital market access rather than US cannabis revenue. Its current focus has pivoted substantially toward psychedelic therapies via Clarion Clinics rather than cannabis commercialisation. It would likely catch a sentiment bid on any formal rescheduling announcement given its Nasdaq listing, but the direct commercial linkage to US marijuana policy is limited.
It is also worth noting that the Nasdaq and the New York Stock Exchange do not currently allow companies that grow or sell cannabis in the US to list on their exchanges, and that is not expected to change simply because of rescheduling. This structurally limits how much of the commercial opportunity can flow to ASX-listed names, most of which are either clinical-stage or operating adjacent to, rather than within, the US plant-touching market.
What to Watch From Here
For ASX investors, the practical implication is this: a confirmed rescheduling decision will almost certainly produce a short-term rally across the ASX cannabis cohort, consistent with how the sector has responded to every prior regulatory catalyst — domestically and internationally.
Whether any rally as a result of the change is durable depends on two things: whether 280E relief actually flows through to operator earnings, and whether institutional capital begins to re-engage with the sector as a result of a cleaner federal framework. A reclassification by the DEA could see more institutional investment flow into the sector — the major reason current multiples are depressed is lack of institutional ownership. That dynamic — not revenue — is the more plausible near-term catalyst for a re-rating.
The few ASX names with genuine US operational exposure are early-stage enough that any rescheduling tailwind is more likely to assist future capital raising than drive immediate revenue. That is not a reason to dismiss them. It is a reason to size positions accordingly, and to remember that in December 2020, ASX cannabis stocks rallied hard on the TGA announcement — and took years to deliver on the commercial promise that rally implied. Regulatory milestones and revenue milestones are rarely the same thing.
The opportunity is real, but the timeline remains uncertain.
